Top Markets
Coin of the day
Lin BioScience, Inc. Lin BioScience, Inc.

Lin BioScience, Inc.

6696
Rangering i aksjer #5731
Lin BioScience, Inc. is an innovative biopharmaceutical company focused on... Lin BioScience, Inc. is an innovative biopharmaceutical company focused on developing novel therapies across oncology, ophthalmology, and metabolic diseases. Its robust pipeline includes LBS-008, an orally administered treatment currently in Phase 3 clinical trials for adolescent Stargardt disease (STGD1) and Phase 2/3 trials for dry age-related macular degeneration (Dry AMD), both aimed at evaluating its safety and effectiveness. Other key candidates are LBS-007, a natural non-ATP CDC7 inhibitor designed to combat various cancers; LBS-002, an anti-tubulin compound targeting primary and metastatic brain tumors; and LBS-009, an oral medication for non-alcoholic fatty liver disease and Type 2 diabetes. The company is headquartered in Taipei, Taiwan.
Aksjekurs
$29.86
Sist synkronisert: 2026-08-19
Markedsverdi
$2.48B
Endring (1 dag)
4.92%
Endring (1 år)
502.82%
Land
TW
Handel Lin BioScience, Inc. (6696)

Kategori

P/S-forhold for Lin BioScience, Inc. (6696)
P/S-forhold per 2026 TTM: 0
Ifølge Lin BioScience, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/S-forhold på 0.
P/S-historikk for Lin BioScience, Inc. fra 2026 til 2026
P/S-forhold ved hvert års slutt
År P/S-forhold Endre
Ikke nok data for de angitte datoene.
P/S-forhold for lignende selskaper eller konkurrenter
Selskap P/S-forhold Forskjell i P/S-forhold Land
10.17 -
US
10.13 -
NL
2.95 -
AU
11.28 -
US
- -
CH